100 mg/ml

DRUG4 trials

Sponsors

Karolinska University Hospital, Asso De Recherche Cancers Gynecologiques, Oulu University Hospital, Grifols Therapeutics LLC

Conditions

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)LymphomaPatients with a confirmed diagnosis of ovarian small cell carcinoma.Primaari aivolymfomaaensilinjan hoito tai hoito relapoituneessa tai refraktaarissa taudissa

Phase 2

Hyper-CVAD/MA for high-risk aggressive B-cell lymphomas: a single-centre academic phase II trial (HYPERION)

RecruitingCTIS2023-505990-34-00

Karolinska University HospitalLymphoma

Start: 2024-11-08Target: 183Updated: 2024-07-08

Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line small cell ovarian carcinoma of hypercalcemic type

RecruitingCTIS2024-515310-40-01

Asso De Recherche Cancers GynecologiquesPatients with a confirmed diagnosis of ovarian small cell carcinoma.

Start: 2021-08-04Target: 27Updated: 2026-01-22

Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous system lymphoma

Not yet recruitingCTIS2024-519046-79-00

Oulu University Hospitalensilinjan hoito tai hoito relapoituneessa tai refraktaarissa taudissa, Primaari aivolymfomaa

Target: 100Updated: 2024-12-20

Phase 3

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Not yet recruitingCTIS2025-522165-30-00

Grifols Therapeutics LLCChronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Target: 6Updated: 2026-07-07